Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Core Viewpoint - Xenon Pharmaceuticals' experimental epilepsy drug azetukalner has successfully met its primary endpoint by demonstrating a statistically significant reduction in focal onset seizures during a late-stage trial [1] Company Summary - Xenon Pharmaceuticals plans to submit a marketing application for azetukalner to the U.S. Food and Drug Administration in the third quarter [1] - Following the announcement, shares of Xenon Pharmaceuticals increased by 16.5% in premarket trading [1] Industry Summary - The drug is aimed at treating focal onset seizures, a specific type of epilepsy that originates in one area of the brain [1]